|
1
|
Sabra MM, Grewal RK, Ghossein RA and
Tuttle RM: Higher administered activities of radioactive iodine are
associated with less structural persistent response in older, but
not younger, papillary thyroid cancer patients with lateral neck
lymph node metastases. Thyroid. 24:1088–1095. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prpic M, Dabelic N, Stanicic J, Jukic T,
Milosevic M, et al: Adjuvant thyroid remnant ablation in patients
with differentiated thyroid carcinoma confined to the thyroid: a
comparison of ablation success with different activities of
radioiodine (I-131). Ann Nucl Med. 26:744–751. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee SM, Lee JW, Kim SY, Han SW and Bae WK:
Prediction of risk for symptomatic sialadenitis by post-therapeutic
dual (131)I scintigraphy in patients with differentiated thyroid
cancer. Ann Nucl Med. 27:700–709. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bonnema SJ and Hegedus L: Radioiodine
therapy in benign thyroid diseases: effects, side effects and
factors affecting therapeutic outcome. Endocr Rev. 33:920–980.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagayama H, Ooi J, Tomonari A, et al:
Severe immune dysfunction after lethal neutron irradiation in a JCO
nuclear facility accident victim. Int J Hematol. 76:157–164. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zarybnicka L, Sinkorova Z, Sinkora J, et
al: Sensitivity of porcine peripheral blood leukocytes to gamma
irradiation in vivo, in vitro and ex vivo. Int J Radiat Biol.
87:491–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watanabe N, Kanegane H, Kinuya S, et al:
The radiotoxicity of 131I therapy of thyroid cancer:
assessment by micronucleus assay of B lymphocytes. J Nucl Med.
45:608–611. 2004.PubMed/NCBI
|
|
8
|
Erselcan T, Sungu S, Ozdemir S, Turgut B,
Dogan D and Ozdemir O: Iodine-131 treatment and chromosomal damage:
in vivo dose-effect relationship. Eur J Nucl Med Mol Imaging.
31:676–684. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ballardin M, Gemignani F, Bodei L, et al:
Formation of micronuclei and of clastogenic factor(s) in patients
receiving therapeutic doses of iodine-131. Mutat Res. 514:77–85.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gutierrez S, Carbonell E, Galofre P, Creus
A and Marcos R: Cytogenetic damage after 131-iodine treatment for
hyperthyroidism and thyroid cancer. A study using the micronucleus
test. Eur J Nucl Med. 26:1589–1596. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
M'Kacher R, Schlumberger M, Legal JD,
Violot D, Beron-Gaillard N, et al: Biologic dosimetry in thyroid
cancer patients after repeated treatments with iodine-131. J Nucl
Med. 39:825–829. 1998.PubMed/NCBI
|
|
12
|
Vrndić OB, Milošević-Djordjević OM,
Mijatović Teodorović LC, et al: Correlation between micronuclei
frequency in peripheral blood lymphocytes and retention of 131-I in
thyroid cancer patients. Tohoku J Exp Med. 229:115–124. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takahashi K, Monzen S, Eguchi-Kasai K, Abe
Y and Kashiwakura I: Severe damage of human megakaryocytopoiesis
and thrombopoiesis by heavy-ion beam radiation. Radiat Res.
168:545–551. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Monzen S, Yoshino H, Kasai-Eguchi K and
Kashiwakura I: Characteristics of myeloid differentiation and
maturation pathway derived from human hematopoietic stem cells
exposed to different linear energy transfer radiation types. PLoS
One. 8:e593852013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
EPR-BIODOSIMETRY 2011, . Cytogenetic
Dosimetry: Applications in Preparedness for and Response to
Radiation Emergencies. IAEA; Vienna: 2011
|
|
16
|
Fonseca TL, Correa-Medina M, Campos MP, et
al: Coordination of hypothalamic and pituitary T3 production
regulates TSH expression. J Clin Invest. 123:1492–1500. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Monzen S and Kashiwakura I:
Radioprotective effects of (-)-epigallocatechin-3-gallate on human
erythrocyte/granulocyte lineages. Radiat Prot Dosimetry.
152:224–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takahashi K, Monzen S, Hayashi N and
Kashiwakura I: Correlations of cell surface antigens with
individual differences in radiosensitivity in human hematopoietic
stem/progenitor cells. Radiat Res. 173:184–190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vrndić O, Milošević-Djordjević O,
Djurdjević P, et al: Radioiodine therapy accelerates apoptosis in
peripheral blood lymphocytes of patients with differentiated
thyroid cancer. Neoplasma. 60:568–575. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hazawa M, Hosokawa Y, Monzen S, Yoshino H
and Kashiwakura I: Regulation of DNA damage response and cell cycle
in radiation-resistant HL60 myeloid leukemia cells. Oncol Rep.
28:55–61. 2012.PubMed/NCBI
|
|
21
|
Stiff T, Cerosaletti K, Concannon P,
O'Driscoll M and Jeggo PA: Replication independent ATR signaling
leads to G2/M arrest requiring Nbs1, 53BP1 and MDC1. Hum Mol Genet.
17:3247–3253. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Monzen S, Osuda K, Miyazaki Y, et al:
Radiation sensitivities in the terminal stages of megakaryocytic
maturation and platelet production. Radiat Res. 172:314–320. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maia GA, Renó Cde O, Medina JM, et al: The
effect of gamma radiation on the lipid profile of irradiated red
blood cells. Ann Hematol. 93:753–760. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dorgalaleh A, Mahmoodi M, Varmaghani B, et
al: Effect of thyroid dysfunctions on blood cell count and red
blood cell indices. Iran J Ped Hematol Oncol. 3:73–77.
2013.PubMed/NCBI
|
|
25
|
Schindhelm RK, ten Boekel E, Heima NE, van
Schoor NM and Simsek S: Thyroid hormones and erythrocyte indices in
a cohort of euthyroid older subjects. Eur J Intern Med. 24:241–244.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alcelik A, Aktas G, Eroglu M, et al:
Platelet function in euthyroid patients undergoing thyroidectomy in
women. Eur Rev Med Pharmacol Sci. 17:2350–2353. 2013.PubMed/NCBI
|
|
27
|
Pilli T, Brianzoni E, Capoccetti F, et al:
A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine
administered doses for recombinant thyrotropin-stimulated
postoperative thyroid remnant ablation in differentiated thyroid
cancer. J Clin Endocrinol Metab. 92:3542–3546. 2007. View Article : Google Scholar : PubMed/NCBI
|
